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9.1 INTRODUCTION 
9.1.1 Scope 
Animal research in recent years has produced many advances in understanding of the 
operation of gastrointestinal (GI) controls of eating and their interactions with other 
mechanisms.  The most progress has been made in hormonal controls in laboratory 
mouse and rat models.  This chapter briefly reviews this literature.  We emphasize the 
normal physiological operation of the controls because we believe this information is the 
most relevant aspect of animal models for the development of selective, therapeutically 
useful controls of disordered human eating.1  Further information on this very active 
research area is available in several recent detailed reviews of GI controls of eating.2-7 
 
In animals, one is limited to the study of behavior, although subjective processes, such as 
food hedonics, can be modeled with appropriate behavioral tests.  The elemental 
movements of eating – licking, chewing, swallowing, etc. - are functionally organized by 
the brain into the molar functional unit of eating, the meal.  Thus, it seems to make 
neurological and psychological sense to analyze eating in terms of the controls of meal 
initiation (usually called hunger), maintenance of eating during the meal (one aspect of 
food reward), meal termination (satiation), and inhibition of eating following meals 
(postprandial satiety). The best investigated of these is the control of satiation.  
 
Information related to many GI functions is relayed to the brain and affects eating.  The 
principal means of communication between gut and brain are hormonal, i.e., 
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gastrointestinal and pancreatic peptides whose release is affected by eating, and neural, 
i.e. vagal and spinal visceral afferent neural signals originating in the gut.  Table 1 lists 
gut peptides that presently appear to have signal functions controlling eating, and Table 2 
lists potential neural controls arising from the stimulation of gut receptors. Because it is 
beyond our scope to review each of these in detail, we focus on a few examples that 
illustrate the key issues involved in establishing GI signals as normal physiological 
controls of eating. Further, we include the pancreatic hormone amylin, which acts as a 
satiating hormone similar to gut-derived signals and which interacts with them. We also 
discuss the operation of these GI signals in animal models of overeating and obesity. 
Finally, we close with a discussion of some perspectives relevant to the translation of 
animal physiology into human therapeutics. 
 
9.1.2 Physiological relevance of gut hormones in eating 
Hormones have been under consideration as physiological controls of eating for many 
years.  Criteria for evaluating their physiological status have evolved together with 
progress in endocrinology in general. Table 3 gives a recent version of such criteria, 
which we use in evaluating the effects of the several hormones that we consider here. 
 
9.1.3 Integrative context 
GI signals, together with signals originating in the oropharynx, form a primordial 
mechanism controlling eating, present even in animals lacking a central nervous system.  
These primordial controls continue to operate in mammals, although they are modulated 
by numerous more recently evolved mechanisms, related, for example to the homeostatic 
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control of metabolism and energy balance.  In addition, phylogeny has strongly tended 
toward increasing plasticity in behavior and physiology, and eating is no exception.  The 
evidence for this is obvious in human eating, which is so strongly individuated by culture 
and individual experience that the operation of the underlying physiology is often 
difficult to discern.  Nevertheless, GI and other primordial controls of eating do operate 
in humans, and form the basis on which other physiological controls as well as the 
influences of learning and cognition are overlaid.   
 
9.2 GASTRIC SIGNALS 
 
9.2.1 Gastric volume 
The upper gastrointestinal tract is richly innervated with mechanoreceptors that are 
stimulated by various aspects of gut loading during and after meals and that signal the 
brain via both vagal and splanchnic visceral afferents. The effects of gastric volume on 
eating in rats have been elegantly analyzed using gastric cannulas in combination with 
chronic pyloric cuffs that can be inflated during meals to limit food stimuli to the 
oropharynyx and stomach.17  The key findings are: (1) when gastric cannulas are used to 
prevent ingested liquid food from accumulating in the stomach, meal size is dramatically 
increased; (2) when ingested food is prevented from entering the intestines by inflating 
pyloric cuffs, meal size is about normal; (3) when fluid loads are infused into the stomach 
of rats with closed pyloric cuffs, eating is inhibited in proportion to the volume infused, 
and (4) the effect of gastric fill on eating is identical whether nutrient or non-nutrient 
loads are used.   
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These data indicate that gastric volume is an adequate stimulus for mechanoreceptors that 
can contribute to the control of eating.  The normal contribution of this signal to eating, 
however, appears to be small.  First, intragastric infusions inhibit eating in rats with 
closed pyloric cuffs only when the total gastric fill (ingesta plus infusion) is markedly 
larger than the control meal size.  Second, the dose-response relation between infusion 
volume and amount less eaten is relatively flat, such that the behavior does not nearly 
compensate for the infusion.  And third, because normal gastric emptying is prevented in 
the cuff-closed condition, the gastric volume at meal end is markedly larger than the 
gastric volume at the end of a similarly sized meal in the cuff-open (normal) condition.  
Indeed, gastric emptying usually proceeds at a surprisingly brisk pace during the meal, 
especially when liquids are eaten. In both rats and rhesus monkeys, the intrameal rate of 
gastric emptying of liquid diet is about five times the post-meal rate.17   
 
Because of its key role in the distribution of ingesta in the gastrointestinal tract, gastric 
emptying is a highly regulated and adaptable function with numerous hormonal and 
neural controls.   The fact that some of these controls affect eating independent of their 
influence on gastric emptying (for example, cholecystokinin [CCK]), complicates 
analysis of the effects of gastric emptying per se on eating. The influence of gastric 
emptying on eating is further complicated by the obvious fact that gastric emptying both 
decreases the intensity of gastric signals and increases the intensity of intestinal and 
postabsorptive signals.   Importantly, the fact that at meal end there are significant 
amounts of ingesta both in the stomach and at postgastric sites suggests the possibility 
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that gastric and postgastric signals interact in the normal control of eating.  Evidence for 
such interactions is considered in the following sections.   
 
9.2.2 Food viscosity 
 
The speed of gastric emptying varies with the physical properties of a diet. Solid food 
empties slower from the stomach than low viscosity, liquid food of similar energy content. 
Davidson and Swithers recently tested the effect of the viscosity of premeals on 
subsequent food intake in rats.23 Their key findings were: (1) rats ate more during a 1 h-
test meal after a low-viscosity premeal than after a high-viscosity premeal; (2) this 
phenomenon was due to the physical viscosity of the premeal rather than the nature of the 
thickening agent used; (3) rats chronically offered a low-viscosity food in addition to 
chow gained more body weight than rats that were offered a similarly palatable high-
viscosity supplement or rats offered chow alone. These findings in rats suggest that high-
energy, low-viscosity foods, such as many soft drinks, may contribute to excessive body 
weight gain in humans. 
 
9.2.3 Ghrelin 
 
Ghrelin, a hormone discovered in 1999, is the endogenous ligand for the growth hormone 
secretagogue receptor (GHS-R).  Ghrelin is expressed mainly in the stomach, but also in 
the brain and other tissues. Gastric ghrelin has attracted great interest because (1) it is the 
only gut peptide whose secretion is stimulated during fasting and inhibited by eating, and 
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(2) it is the only gut peptide whose administration stimulates eating, as now shown in rats 
and humans.24,25 Furthermore, chronic peripheral or central ghrelin administration 
stimulates food intake, decreases energy expenditure and induces weight gain.   
  
9.2.3.1 Physiological relevance.  According to the criteria of Table 3, the physiological 
status of ghrelin as a hunger signal is not fully established. (1) In several species, 
including humans and rats, plasma ghrelin levels rise shortly before meals are initiated 
and fall rapidly when food is consumed. However, in humans there is also a nocturnal 
rise and fall in plasma ghrelin that is not associated with meals, so ghrelin alone is 
insufficient to account for meal initiation. (2) The preponderance of evidence (e.g., ref. 
26) indicates that the eating-stimulatory effect of ghrelin is mediated by the GHS-Rs in the 
brain, especially those in the hypothalamic arcuate nucleus (Arc) and the brainstem. As 
neurons in these areas also secrete ghrelin, the relative contributions of hormonal and 
neuronal ghrelin to its eating effect remain unclear. (3) It is unknown whether mimicking 
physiological ghrelin levels, especially the physiological pre-prandial rise in circulating 
ghrelin, is sufficient to trigger eating. (4) Removal of ghrelin secreting cells would 
require gastrectomy, clearly an intervention with numerous other effects. The ghrelin 
knockout mouse, however, exhibits the expected leaner phenotype under some 
conditions.27  Thus, the criterion for removal and replacement is only partially fulfilled. 
(5) GHS receptor antagonists have been shown to reduce feeding in mice, but the potency 
and specificity of ghrelin antagonists are still not ideal.28 Blocking endogenous ghrelin 
action by specific ghrelin spiegelmers may offer an interesting alternative.29   
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Because plasma ghrelin levels fall rapidly during meals, it is conceivable that the 
reduction in ghrelin signaling contributes to satiation. Indeed, recent data in humans 
suggest that the mealtime inhibition of ghrelin secretion is mediated by the increase in 
secretion of the satiation signal CCK.30 Consistent with the hypothesis that reductions in 
plasma ghrelin secretion signal satiation, (1) ghrelin administration often increases meal 
size in rats and affects the timing of meals, and, (2), ghrelin may interact with satiation 
signals in the control of eating.3,31 
 
9.2.3.2 Ghrelin as an inverse adiposity signal. Ghrelin may contribute to the control of 
body weight as well as to the initiation of individual meals. Indeed, initial reports suggest 
that ghrelin meets the three principal criteria proposed for an adiposity signal.8,14 That is: 
(1)  Endogenous fasting ghrelin levels are inversely correlated with body weight in 
humans and rats (although diet composition also appears to be a major determinant of 
ghrelin levels independent of body weight);25 (2) chronic ghrelin administration increases 
adiposity and body weight in mice and rats (although the relative contributions of eating 
and energy expenditure remain unclear);32 and (3) chronic administration of specific 
ghrelin spiegelmers has recently been shown to reduce weight gain in mice offered a 
high-fat diet.29 Hence, we consider the hypothesis that ghrelin is an adiposity signal 
controlling eating to be plausible and in need for further verification. 
  
9.2.3.3 Ghrelin and Obesity. In addition to the chronic spiegelmer results mentioned 
above, rats and mice that were actively immunized with an anti-ghrelin vaccine did not 
eat in response to peripheral ghrelin, although they did eat in response to central ghrelin, 
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and gained slightly less body weight than control animals (T.A. Lutz, unpublished). 
Hence, it is possible that antagonism of endogenous ghrelin signaling is sufficient to 
control body weight in rats.  Whether this is also true in animal models of obesity is not 
yet known.  
 
9.3 INTESTINAL SIGNALS 
 
9.3.1 Intestinal chemoreception 
 
Nutrient and osmotic stimuli acting in the small intestine appear to play physiological 
roles in satiation (see Ritter7 for a critical review).  Nutrients involved include long chain 
fatty acids, most carbohydrates, and proteins.  Both neural (especially vagal afferents) 
and endocrine (see next sections) signals relay this information to the brain.  Nonnutritive 
osmotic stimuli have been shown to affect food intake within the physiological range of 
intrameal intraluminal osmotic pressure, i.e., about 700 mosmol/l in swine and rats.7   
 
The most extensive information related to nutrient-related intestinal satiation or satiety 
exists for lipids.7  The reduction in eating induced by intraduodenal lipids depend largely 
on pre-absorptive sensing of fatty acids and monoglyceride. Inhibition of pancreatic 
lipase, for example by orlistat (Hoffman LaRoche, Basel, Switzerland), attenuates the 
reduction of food intake induced by intestinal triglyceride infusion. Furthermore, long 
chain fatty acids seem to be preferentially involved because intestinal infusions of 
glycerol or fatty acids with chain length of 12 C or less elicited less satiation.  Thus, the 
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full eating-inhibitory potential of fatty acids apparently is realized when fatty acids are 
absorbed via the chylomicron pathway rather than directly into the hepatic portal vein.  
The major mediators of intestinal lipid-induced satiation or satiety appear to be signals 
released during absorption, such as the peptides CCK, glucagon-like peptide-1 (GLP-1), 
peptide YY (PYY), and apolipoprotein A-IV (Apo A-IV), or oleoylethanolamide (OEA) 
(see sections below).   
 
Among carbohydrates, glucose seems to be the major intestinal signal.  Blockade of 
carbohydrate digestion, e.g. by acarbose, reduced the effect of intraduodenal infusions of 
maltotriose on food intake.7 The afferent signal induced by carbohydrates seems 
unrelated to glucose uptake into the enterocytes because blockade of the sodium-linked 
glucose transporter with phlorizin did not affect carbohydrate-induced intestinal satiation. 
Some specific amino acids, especially L-phenylalanine and L-tryptophan, also seem to be 
important intestinal signals.  The transduction mechanisms involved are unknown.  
 
Finally, vagal afferents are clearly the major gut-brain pathway mediating intestinal 
nutrient-related signals.  After subdiaphragmatic vagal deafferentation, the most selective 
and complete method for lesions of gut vagal afferents, rats no longer ate less in response 
to intraduodenal infusions of lipid, carbohydrate, or fat. 
 
9.3.2 Cholecystokinin (CCK) 
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CCK is synthesized by I cells in the proximal small intestinal mucosa. Their apical 
surfaces are exposed to intraluminal stimuli, and CCK is secreted through the basolateral 
membrane. Gibbs and colleagues were the first to show that intraperitoneal injections of 
CCK selectively inhibit eating.33 CCK seems to be a pure satiation signal because 
administration of CCK at meal onset decreases meal size in animals and humans with 
little effect on the following intermeal interval5,6 and, except at high doses, without 
causing aversive or toxic effects. CCK remains the most investigated gut peptide that 
controls eating (see e.g. work by the groups of G.P. Smith and J.G. Gibbs, T. Moran and 
P. McHugh, R. Ritter, R. Reidelberger, C. Beglinger).  
 
9.3.2.1 Physiological relevance. Here, we briefly summarize the evidence that in both 
rats and humans CCK meets the criteria of Table 3 for a physiological satiation signal. (1) 
In contrast to humans, plasma CCK concentration has rarely been demonstrated to 
increase during a meal in rats.5 Together with other data, in particular that intraperitoneal 
administration of CCK is relatively more potent than intravenous CCK to inhibit eating, 
this suggests that CCK acts mainly as a paracrine rather than as an endocrine signal in 
rats. The paracrine action also suggests that CCK secreted from enteric neurons may be 
important in CCK satiation. Eisen et al. suggested that CCK may in part have an 
endocrine mode of action in rats, with a target site in the liver, and that the form of the 
CCK peptide may be a factor influencing the site of action.34 In any case, however, 
measurements of neither the molecular form nor the concentrations of prandial CCK in 
the extracellular fluid of the proximal gut or in the hepatic portal vein have been reported. 
(2) In rats, the results of close-arterial infusions, pylorectomies, and selective vagotomies 
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suggest that the satiating action of CCK is mediated by CCKA receptors in vagal afferents 
and in the pyloric circular muscle. As mentioned above, CCKA receptors in the liver may 
also be involved. The role of CCKA receptors in several brain areas, including the NTS 
remains uncertain. (3) Again as mentioned above, in rats the data required to establish a 
physiological paracrine mode of action are not available. In contrast, in humans CCK 
apparently acts via an endocrine mode, and physiological doses of CCK are sufficient to 
inhibit eating. (4) To study removal and replacement is difficult to perform because CCK 
producing cells are distributed widely. Surgical removal of CCK would require removal 
of much of the small intestine.  Findings in rats with a spontaneously mutated CCKA 
receptor at least in part support the criterion (reviewed in ref. 5,6).  In these rats, meal size, 
total daily food intake and body weight are all increased. However, CCKA receptor 
knockout mice have an unchanged adult body weight and daily food intake. 
Unfortunately, meal patterns have not been determined. Whether this species difference 
is due to different receptor distributions is unknown at present.6 (5) The criterion of 
antagonism has been well established in rats because CCK receptor antagonists increase 
meal size and block the satiating effect induced by intraduodenal infusions of fat, which 
at least in part is mediated by CCK. This evidence also indicates a peripheral site of 
action of endogenous CCK because it includes tests both with antibodies, which do not 
cross the blood-brain barrier, and with local infusions of receptor antagonists into the gut 
circulation. 
 
9.3.2.2 Mechanisms of CCK’s satiation effect. Peripheral CCKA receptors signal the 
brain via all four subdiaphragmatic vagal branches.35 The involvement of CCKA and 
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CCKB receptors in the dorsal vagal complex or in the area postrema (AP) have also been 
suggested. These receptors, however, may be activated by neural, locally released CCK.  
The same is true for the CCKA receptors in the dorsomedial hypothalamus.  This situation 
may be part of a more general phenomenon that the same molecules are released from 
peripheral nerves or glands as well as from neurons in the brain.  Thus, in the case of 
CCK, central receptors, perhaps in the AP, may mediate the decreases in food intake and 
conditioned taste aversions that can be elicited by larger doses of CCK (i.e, 
intraperitoneal injection of > 8 µg/kg CCK-8), even in vagotomized rats. 
 
For CCK, as well as for most other eating-control signals, little is known about 
information processing in the brain or about the extensive convergence of the many 
signals that are activated simultaneously. Neural signals from the gut, including the 
vagally mediated CCK signal, project to the nucleus of the solitary tract (NTS).  In the 
case of CCK, central processing seems to involve catecholaminergic and GLP-1-ergic 
neurons in the NTS, NTS neurons that express the melanocortin-4 receptor (MC4R) that 
apparently originate in the hypothalamus,36 and, at least in females, NTS neurons 
expressing estrogen receptor-α (ERα).37  Further, CCK satiation also depends on brain 
serotonin. Importantly, most of this work has involved tests of exogenous CCK, and it is 
not clear whether the neural processing of exogenous CCK is identical to that of 
endogenous CCK.  For example, it seems likely that smaller doses of CCK or 
endogenous CCK, which signal via the vagus, and larger doses of CCK, which signal at 
least in part independent of the vagus, do not activate identical neural networks. 
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9.3.2.3 CCK and Obesity. Numerous studies suggest that CCK is acutely effective in a 
wide variety of models of obesity, e.g. rats with lesions of the ventromedial 
hypothalamus (which included the Arc), ob/ob mice, Zucker  fa/fa rats, and  rats with 
dietary-induced obesity. However, in Koletsky fak/ fak rats, CCK decreased meal size less 
than in lean control rats39 (but see ref. 38). The deficit in CCK satiation was rescued by 
leptin receptor expression via adenoviral gene therapy into the Arc. Therefore, leptin may 
control meal size through an obligatory interaction with CCK, consistent with Smith’s 
theory of the direct and indirect control of meal size.40     
 
The effects of repeated CCK administration on eating and body weight suggest that CCK 
effectively reduced meal size, total food intake, and body weight when meal frequency is 
controlled, but not in freely feeding rats. West et al. showed that when CCK was infused 
intraperitoneally before each spontaneous meal for six days in rats, meal size was reduced 
throughout the study with no sign of tolerance.41 However, meal frequency rapidly 
increased to return total daily food intake to control level. Body weight gain was reduced 
for only one day.  Similar results have been reported in free-feeding rats when CCK was 
continuously infused for several days and when CCKA receptor agonists were tested 
chronically.  In contrast, when CCK was intraperitoneally injected before each of three 
scheduled daily meals for three weeks, CCK consistently reduced meal size and led to 
significant weight loss (reviewed in ref. 42).  
 
 
9.3.3 Intestinal glucagon-like peptide-1 (GLP-1) 
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Glucagon-like peptide-1 (GLP-1) is a product of the prepro-glucagon gene that is 
produced mainly in intestinal L-cells and also in a specific group of neurons in the NTS 
in the brainstem.43 Exendin-4 is a GLP-1 analogue which has an extended half-life over 
GLP-1 because, especially in rodents, the active form of GLP-1 (GLP-1[7-36amide]) is 
rapidly degraded through action of dipeptidyl-peptidase IV. 
  
9.3.3.1 Effects of GLP-1 on food intake. In rodents and humans, food intake results in 
an immediate release of GLP-1 into the blood. Central and peripheral GLP-1 each 
produce dose-dependent reductions in food intake in rats and mice.44 The reduction in 
food intake results mainly from a decrease in meal size, but meal number is also reduced, 
at least at higher doses. Chronic delivery of exendin-4 reduces body weight gain in mice 
by specifically reducing body fat mass.45 Interestingly, however, mice lacking the GLP-1 
receptor have unaltered body weight compared to controls. Hence, the GLP-1 receptor is 
probably not a single critical component in the control of food intake. 
 
9.3.3.2 Physiological relevance.43 Four of the five criteria (Table 3) qualifying an 
anorectic substance to be of physiological relevance have been investigated in rats. (1) 
Eating increases GLP-1 secretion: the amount of GLP-1 secreted during a meal in rats, 
however, has not yet been carefully characterized. (2) GLP-1 receptors are present in 
GLP-1’s presumed site(s) of action, i.e. the gastrointestinal tract and certain brain nuclei, 
including the brainstem. (3) To our knowledge, this criterion has not been investigated in 
rats. (4) The criterion of removal and replacement is difficult to investigate because it 
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would require ablation of the GLP-1 producing cells. Obviously, this has been done 
neither in humans nor in experimental animals. The effect of removal of receptors has 
been tested in GLP-1 receptor knockout mice. These mice are insensitive to exogenous 
GLP-1, but their body weight was unchanged compared to controls. Whether this 
represents opposing effects on spontaneous meal size and meal frequency, as discussed in 
the case of CCK, is not known. Surprisingly, however, the fasting-induced feeding 
response in the knockout mice was also similar to that in wildtype controls. Hence, at 
least under these conditions endogenous GLP-1 does not seem to play a necessary role in 
the regulation of eating. (5) The final criterion of receptor antagonism has been 
investigated using the GLP-1 receptor antagonist exendin 9-39. Ad libitum fed rats that 
were treated with exendin-9-39 centrally ate more than control animals (e.g., ref. 44). 
Hence, blockade of endogenous central GLP-1 signaling seems to lead to increased food 
intake. Whether antagonism of peripheral GLP-1 signaling has a similar effect is not 
known. 
In summary, GLP-1 does not yet fully meet all criteria that are required for a hormone to 
be a physiological regulator of eating, but the available data are encouraging. It is 
important to note in this context, however, that the relationship of the aversive effects of 
GLP-1 and its agonist exendin-4 that occur under certain conditions (see below) and the 
hypothesized satiation effect needs to be clarified. 
 
9.3.3.3 Site of GLP-1 action. Central or peripheral delivery of GLP-1 or exendin-4 
activate neurons, as characterized by c-Fos immunocytochemistry, in specific brain areas 
in the brainstem (e.g., AP, NTS) and hypothalamus (e.g., Arc, paraventricular nucleus).44 
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The central c-Fos pattern induced by peripheral exendin-4 and amylin (see below) is 
similar, and amylin and GLP-1 co-activate AP neurons.8 However, the anorectic effect of 
exendin-4, unlike amylin, is not blocked in AP lesioned rats while vagal blockade by 
vagotomy or capsaicin-pretreatment abolished exendin-4’s but not amylin’s effect. 
Consistent with a peripheral component in GLP-1’s anorectic effect, central 
administration of the GLP-1 antagonist exendin-9-39 was unable to block the anorectic 
effect of exendin-4. Surprisingly, however, peripheral co-administration of exendin-9-39 
also did not block exendin-4’s effect. Only simultaneous central and peripheral 
application of the antagonist blocked exendin-4’s effect on feeding in rats (T.A. Lutz, 
unpublished). The potential interaction of central and peripheral GLP-1 receptors remains 
to be clarified. 
 
9.3.3.4 Role of brain GLP-1. The peripheral and the central GLP-1 system in the NTS 
do not seem to interact directly because an anorectic dose of peripheral exendin-4 did not 
activate GLP-1ergic NTS neurons. In contrast, high doses of peripheral CCK (100 µg/kg), 
which clearly produced non-specific, aversive effects, did activate these neurons.46 Thus, 
whether central GLP-1 mediates the physiological satiating effect of GLP-1, CCK or 
other anorectic satiating hormones is questionable. 
 
Central GLP-1 may mediate the anorectic effect of leptin because the feeding-inhibitory 
effect of central leptin was attenuated by central administration of exendin-9-39. Further, 
restricted feeding decreased prepro-glucagon mRNA in the NTS compared to controls, 
and this effect was prevented by central leptin. The hypothalamic content of 
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immunoreactive GLP-1 paralleled prepro-glucagon mRNA expression in the NTS. Leptin 
may therefore stimulate GLP-1ergic neurons in the NTS; the physiological importance of 
these findings, however, requires further work. 
 
9.3.3.5 GLP-1 and conditioned taste aversions. It seems likely that central GLP-1 is 
involved in mediating the anorectic effects of some aversive stimuli.46 Rinaman has 
shown, e.g., that peripheral administration of sickness-producing agents (e.g., LiCl, 
lipopolysaccharide, high doses of CCK) all produce a strong c-Fos response in GLP-
1ergic neurons of the NTS, whereas other feeding-related stimuli, such as gastric 
distension, did not. Furthermore, both central GLP-1 administration and peripheral 
exendin-4 administration (T.A. Lutz, unpublished) produced strong conditioned taste 
aversions in rats in 2-bottle preference tests.  
Situational effects and species differences appear to be important in GLP-1’s aversive 
effects. For example, Mack et al. reported that a dose of 10 µg/kg exendin-4, i.e. five 
times higher than the doses we found aversive in a conditioned taste aversion test, failed 
to affect another measure of aversion, kaolin intake.45 As to species differences, central 
GLP-1, similar to rats, produced conditioned taste aversion in wildtype mice, but not in 
GLP-1 receptor-knockout mice. This points to a GLP-1 receptor mediated effect. 
However, LiCl produced taste aversion in both groups of mice, indicating that the GLP-1 
receptor may not be involved in this aversive behavior under these conditions in mice. 
Furthermore, the GLP-1 antagonist exendin-9-39 reduced the aversive effect of GLP-1, 
but not that of LiCl in mice. Both effects clearly differ from rats.47  
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9.3.4 Peptide YY (PYY) 
 
Peptide YY is synthesized and released mainly by intestinal L-cells, i.e., the same cells 
that synthesize GLP-1. Some data indicate that the two peptides are not always co-
secreted, although the mechansims for the dissociation are unclear. Two main forms of 
PYY appear in the circulation, full-length PYY1-36 (which we call PYY here) and its 
more active cleavage product, PYY3-36. Interestingly, the same enzyme, dipeptidyl 
peptidase-IV (DPP IV), that inactivates circulating GLP-1[7-36amide] catalyzes the 
formation of PYY3-36, so that the active GLP-1 has a much shorter plasma half-life than 
PYY3-36.  L-cells release PYY, like GLP-1, in response to food intake, especially lipids.  
Beglinger and his colleagues have recently shown that in humans, secretion of PYY3-36 
after intraduodenal lipid infusions depends on CCK release – that is, if a CCKA receptor 
antagonist was administered, PYY3-36 did not appear in the plasma following the lipid 
infusions.30   
 
PYY has affinity to all subtypes of Y receptors, whereas PYY3-36 predominantly 
activates Y2 receptors. Centrally administered PYY has long been known to increase 
food intake, presumably via activation of Y1 or Y5 receptors.  Batterham and colleagues 
recently provided the first evidence that peripheral PYY3-36 also decreases eating in 
rats.48 This effect is apparently mediated by Y2 receptors because it was attenuated by Y2 
receptor antagonist and absent in Y2 receptor knockout mice.48 Many investigators have 
reported that they were unable to reproduce the eating-inhibitory effect of peripheral 
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PYY in rats (e.g., ref. 16,49).  This is likely due to differences in adaptation to test 
conditions, circadian timing, or other procedureal differences.3 
 
The site where PYY3-36 acts to inhibit eating is not clear. Evidence in favor of both a 
central site of action in the Arc as well as a peripheral, vagally mediated action have been 
presented. In the original publication by Batterham and colleagues, it was reported that 
PYY3-36 specifically increased the firing rate of POMC neurons located in the Arc in an 
in vitro slice preparation in mice.48 Further, a Y2 receptor agonist increased the release of 
the splicing product of the POMC gene, alpha-melanocyte stimulating hormone (alpha-
MSH), from rat hypothalamic explants containing the Arc. Hypothalamic alpha-MSH 
decreases feeding by acting on paraventricular neurons. Hence, the increase in firing rate 
in POMC neurons may coincide with the release of alpha-MSH. At the same time, 
neuropeptide Y (NPY) expression and the release of NPY from hypothalamic explants 
was decreased. The latter effects correspond to our own findings that full length PYY 
inhibited ghrelin activated neurons in rat brain slices of the medial Arc.50 These neurons 
presumably express NPY and mediate the orexigenic effect of ghrelin. In apparent 
contrast to these indications that PYY may have a direct action in the Arc, Abbott et al. 
showed that the anorectic effect of peripheral PYY3-36 was blocked in vagotomized rats 
and in rats with lesions of the “brainstem-hypothalamic pathway”.51  
 
Peripheral PYY3-36 induced expression of c-Fos protein in the brainstem, specifically in 
the AP and NTS,16 and in the Arc.51 Vagotomy prevented PYY3-36-induced expression 
of c-Fos protein in the Arc. Whether NTS c-Fos expression also depends on the vagus has, 
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to our knowledge, not been investigated. Interestingly, however, and unlike GLP-1, 
PYY3-36’s effect on feeding was not blocked by capsaicin, so that it seems unlikely that 
vagal afferents are directly involved in the anorectic action.52 Clearly, more research is 
needed to define the primary site of action (periphery? brainstem? Arc?) of peripheral 
PYY and PYY3-36. 
 
In contrast to the original report, high doses of PYY3-36 have been reported to induce 
conditioned taste aversion in rodents and to cause nausea in humans.16,48 However, low-
dose intravenous infusions of PYY3-36 reduced feeding without aversive effects in rats.16  
 
9.3.5 Interaction of GLP-1 and PYY3-36.  
 
Because food intake triggers the release of numerous hormones from the gastrointestinal 
tract that individually have been implicated in the control of food intake, understanding 
their functional and mechanistic interactions is of both physiological and 
pharmacological interest. One of the more interesting interactions is exemplified by the 
feeding effects of simultaneous administration of PYY3-36 and GLP-1. Combined 
subthreshold doses of GLP-1 and PYY3-36 (10 and 1 nmol/kg, respectively) significantly 
reduced feeding in rats.53 (See also ref. 52). In addition, suprathreshold doses of GLP-1 
and PYY3-36 (100 nmol/kg each), which individually each decreased food intake 
significantly, led to a significantly stronger effect when combined. These findings are 
consistent with immunohistochemical studies showing that the combination of GLP-1 
and PYY3-36, but not either peptide alone, increased c-Fos expression in the Arc.53 
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9.3.6 Apolipoprotein A-IV 
 
Apolipoprotein A-IV (Apo A-IV) is produced in enterocytes during the digestion of lipids 
containing long chain (C > 12) fatty acids and is released into the lymph, thus reaching 
the bloodstream much slower than the gut hormones considered before. Fujimoto and 
colleagues were the first to show that Apo A-IV reduces food intake in rats.7,9. Apo A-IV 
may contribute to the reduction in food intake that is seen after intestinal fat infusion in 
rats. Infusion of chylous lymph that was collected from animals after intestinal 
application of fat, but not after intraintestinal saline, reduced feeding in rats, and this 
effect was not observed if Apo A-IV was removed from lymph by immunoprecipitation. 
Interestingly, Apo A-IV is also synthesized in the Arc. Additionally, centrally 
administered Apo A-IV inhibited eating, and administration of Apo A-IV antibodies into 
the third cerebral ventricle stimulated eating and reduced Apo A-IV expression in the 
hypothalamus. Despite these promising data, the role of Apo A-IV in the physiological 
control of food intake is far from being resolved. 
 
9.3.7 Oleoylethanolamide (OEA). 
 
 Recently, the eating-inhibitory effect of the endogenous lipid oleoylethanolamide 
(OEA), which is synthesized in enterocytes in response to food intake, has drawn 
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increased attention.54,55 OEA is synthesized in duodenal and jejunal mucosal cells during 
and after meals, but not in fasted rats. Peripheral, but not central, administration of OEA 
decreases food intake. OEA apparently acts by binding to the transcription factor 
peroxisome proliferator-activated receptor-alpha (PPAR-alpha), which then activates a 
neural pathway. Whether this occurs directly or indirectly and whether vagal afferents, 
spinal visceral afferents, or both are involved are not yet clear.  Interestingly, long lasting 
forms of OEA selectively decrease meal frequency, suggesting that this molecule is 
involved in signaling postprandial satiety. 
 
9.4 PANCREATIC SIGNALS 
 
The pancreatic hormones insulin, amylin, glucagon and somatostatin are all released in 
response to food intake and appear to act as satiating hormones (amylin, glucagon, 
possibly somatostatin and insulin) and adiposity signals (insulin, possibly amylin). In this 
section, we briefly discuss amylin in the control of food intake because amylin interacts 
with CCK to control meal size and because recent advances have made it a likely 
candidate for the first hormonal treatment of obesity. 
 
 
  
9.4.1 Amylin 
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Amylin (or islet amyloid polypeptide) is synthesized by the pancreatic B-cells and co-
secreted with insulin. It is considered an important complement to insulin in the control 
of glucose metabolism.56  Amylin also controls the supply of metabolites by controlling 
eating.4,8,14 Like ghrelin, amylin appears to have a dual role, such that prandial amylin 
secretion contributes to meal-ending satiation and basal plasma amylin levels may act as 
an adiposity signal. 
 
9.4.1.1 Physiological relevance. Amylin has been shown to meet most of the criteria 
summarized in Table 3 for a physiological satiation signal in rats.  (1)  Food intake results 
in a marked increase in plasma amylin concentration that begins within 5 min and whose 
magnitude is correlated with amount eaten.  (2)  All the components of the amylin 
receptor complex – i.e., calcitonin receptor core (CT-R) together with several receptor-
activity modifying proteins (RAMPs) that confer amylin affinity and selectivity – are 
expressed in the AP, where amylin appears to act to inhibit eating.57,58  (3)  Amylin 
infusions that yielded plasma amylin levels close to those measured postprandially 
inhibited eating.59  Possibly, the different kinetics of the plasma amylin concentrations 
after exogenous amylin delivery and after endogenous secretion may have affected the 
results, so that the criterion of the physiological dose may be met.  (4) There is currently 
no method for acute removal of amylin without damaging B-cell function. The amylin 
knockout mouse shows the expected phenotype of overeating and increased adiposity,8 
but the effect of physiological doses of amylin on eating in these mice has not yet been 
tested.  (5) Finally, peripheral or central delivery of amylin antagonists increases eating.  
For example, administration of the amylin receptor antagonist AC 187 into the AP 
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blocked the anorectic effect of intraperitoneally injected amylin and, when administered 
alone, stimulated eating by increasing meal size.60,61 
 
9.4.1.2 Amylin as an adiposity signal. Amylin also appears to meet all the criteria 
proposed for an adiposity signal 8,14 in rats. (1) Basal plasma amylin level is (positively) 
correlated with body adiposity. (2)  Chronic continuous amylin infusion reduces food 
intake and body weight.  (3) Chronic peripheral or central infusion of amylin antagonists 
increased body adiposity.  In addition, the amylin knockout mouse is heavier than 
wildtype controls.  
 
9.4.1.3 Mechanism of amylin action. Amylin acts in the AP to inhibit eating.  (1) Eating 
was inhibited or stimulated, respectively, by injection of amylin or the amylin receptor 
antagonist AC187 directly into the AP.60  (2)  After AP/NTS lesions, peripheral amylin 
no longer inhibited eating.58  Lesions of peripheral neural afferents, in contrast, had no 
effect.8,62  (3) Both peripheral amylin and post-deprivation refeeding increased neuronal 
activation in the AP, as gauged by expression of c-Fos protein, and both responses were 
effectively blocked by AC187.63  (4)  Direct application of amylin onto AP neurons in 
slice preparations led to dose-dependent increases in electric activity.  (5) c-Fos responses 
rostral to the AP that were elicited by peripheral administration of amylin were 
eliminated after AP lesions.  
 
 27
Dopamine (presumable acting in the AP/NTS region), histamine (ventromedial 
hypothalamus), orexin, and melanin concentrating hormone (lateral hypothalamic area) 
neuronal systems have been implicated in amylin signaling.8 
 
9.4.1.4 Amylin and obesity. Amylin or its agonist salmon calcitonin (sCT) effectively 
reduced eating in the ob/ob mouse, the obese Zucker fa/fa rat, and the melanocortin-4 
receptor knockout mouse.62,64,65 Amylin antagonism with peripheral AC187 also 
increased eating in Zucker rats.65 Recent reports of anti-obesity actions in humans, e.g. 
that acute administration of the amylin analogue pramlintide decreased the size of test 
meals by about 20% in non-diabetic obese individuals, 66,67 strongly encourage further 
research in this direction. 
 
9.5 PERSPECTIVES  
 
9.5.1 The translation of animal physiology into human therapeutics. 
 
9.5.1.1 Animal models. Although the value of animal models for human eating is a 
matter of ongoing discussion, the clear consensus among researchers is that progress in 
the physiology of eating absolutely requires animal models.68-71 Many questions can be 
addressed only with methodologies that are difficult or impossible in human subjects. 
Furthermore, it is a validated strategy: physiology is replete with examples of successful 
translation of analyses of physiological mechanisms in animals to those in humans.  
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Accepting that animal models are useful in general leaves open the question as to which 
particular animal model(s) is best suited. On first glance, it would seem logical to use 
phylogenetic relationships as a criterion, but in fact this is probably not so. Our closest 
primate relatives, great apes and old-world primates, are not appropriate research animals 
for many reasons. In addition, most of these species have quite different nutritional 
adaptations; in particular only few are omnivores. Several omnivores have been used in 
eating research, including dogs, swine, rats and mice. Among these species, both classical 
structural taxonomy and more recent molecular phylogenetics place the order of rodents 
closer to primates than are either carnivores or even-toed ungulates (the order including 
swine).72 This general relationship, however, is not necessarily true for any specific 
ancestral gene or phenotype.73,74  The rat, for example, does not have a gall bladder, 
whereas carnivores and swine do. 
 
Many of these points are illustrated by the case of CCK. As described above, the 
pharmacological satiating effect of CCK, discovered in rats in 1973,33 was quickly 
translated into normal weight and obese human subjects.75 A similar progression occurred 
for the satiating effect of endogenous CCK. In this case, a specific behavioral assay – the 
satiating action of intestinal nutrient infusions – that was developed in rats proved 
illuminating in monkeys and humans as well.76,77 This procedure also revealed a species 
difference: although intestinal infusions of lipids increased CCK secretion in all three 
species, intestinal infusions of L-phenylalanine produced CCK release in rats, but not in 
monkeys.78  Work with animals lacking CCKA receptors suggest a similarly important 
species difference in two even more closely related species. That is, as mentioned above, 
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rats with null deletions of the CCKA receptor gene are obese, whereas mice with similar 
mutations are not, apparently because of a difference in the distribution of the CCKA 
receptor in the brain.6,79 
 
Finally, CCK physiology also illustrates the potential of back translation, from humans to 
animals. That is, rats, rather than humans, will presumably be the species of choice to 
determine the mechanisms underlying the necessary role of CCK release for the 
stimulation of PYY3-36 secretion and inhibition of ghrelin secretion by intraduodenal 
lipid recently discovered in humans.30 
 
9.5.1.2 Physiology, Pharmacology and Selectivity. As the foregoing sections make 
clear, numerous manipulations inhibit eating in animals or humans under some conditions.  
Such demonstrations provide no real evidence that the function modeled, such as gastric 
distension or gut hormone secretion during or after eating, physiologically controls eating.  
Rather, such demonstrations merely encourage a program of research to investigate the 
issue.   
 
Consider three alternatives.  (1) The manipulation may mimic a normal or physiologiocal 
endogenous mechanism of appetite.  (2) The manipulation may stimulate a normal 
appetitive behavior, but in a way or at a time that does not occur physiologically, i.e., it 
has a selective but pharmacological effect.  For example, an exogenous homone may 
produce satiation even if the endogenous hormone is not secreted, or is not secreted in 
sufficient amounts, during meals.  (3) The manipulation may affect appetite, but do so by 
eliciting a response that is not part of the normal physiological control of eating, such as 
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illness, aversion, etc.  This is a non-selective effect on appetite.  Such effects can and do 
occur even in the case of exogenous administration of physiological signals, if they are 
given in too high a dose (e.g., CCK) or in the wrong context. 
 
Distinguishing among these alternatives can be very difficult, especially in animal 
research.  Many theoretical and practical criteria have been proposed and continue to 
evolve as new methodologies emerge. It is important to note that even if a peptide does 
not appear to be a likely physiological control of eating, this does not preclude it from 
being a potential pharmaceutical target for appetite control, as long as eating and body 
weight can be influenced without triggering major side effects.   
 
9.5.2 Potentials and problems of gut-brain axis signals in the treatment of obesity 
 
9.5.2.1 Redundancy and synergy. The controls of eating are multifactorial and 
redundant. This may mean that manipulations of individual signals will be ineffective 
because of functionally antagonistic, adaptive responses of others.  On the other hand, 
this also creates the potential for therapies based on simultaneous manipulation of several 
signals. “Cocktail” therapies may provide a means to counteract side effects or 
antagonistic adaptive responses. For example, simultaneous use of a ghrelin-based 
therapy may perhaps prevent increases in meal frequency that might otherwise neutralize 
the decreases in meal size produced by a CCK- or amylin-based therapy. 
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Therefore, we consider the study of interactions of the many signals that control ingestive 
behavior an especially important area in the context of their therapeutic potential. Similar 
to other areas of pharmacological therapeutics, it seems plausible that combination 
therapies for obesity may have the same advantages of increased potency and decreased 
side effects. CCK, the best investigated signal in this regard, has been reported to 
functionally interact with several other peripheral signals (listed in Table 4). Functional 
synergy between CCK and gastric loads has been reported in rats, primates, and humans.  
As to the mechanisms underlying these synergies, CCK and gastrointestinal 
mechanostimulation synergistically increased the electrophysiological activity of vagal 
afferent neurons.  The interaction may depend on activation of 5HT3 receptors in the 
periphery and N-methyl-D-aspartate (NMDA) receptors in the dorsal vagal complex. At 
the hormonal level, the amylin-induced neural signaling may be a necessary part of CCK 
signaling because CCK satiation was reduced by amylin antagonist pretreatment in rats 
and in amylin knockout mice, in which it was rescued by subthreshold doses of amylin.  
The reverse appears not to be true - CCK antagonists had no effect on amylin satiation.8 
 
9.5.2.2 Side effects. Gut-brain axis signals may offer several advantages to the currently 
available therapies in the treatment of obesity in relation to side effects. Many details of 
the physiology of several gut-brain controls have been established, so that the types and 
severity of side effects might be more predictable.  Peripheral side effects may be more 
tractable to treatment, and peripheral signals can be manipulated peripherally, which is in 
general more accessible, selective, predictable, and perhaps more safe than manipulation 
of central neurotransmitter systems. Further, many of the hormonal gut-brain signals are 
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fully coupled hormonal controls.5 This means that ideal timing of agonistic or 
antagonistic therapies can be predicted. As indicated above, perhaps a ghrelin antagonist 
should for example be applied several hours before meals, whereas a CCK or amylin 
agonist should be applied immediately before eating.   
  
Gut-brain axis manipulation often causes gastrointestinal dysfunction and nausea as side 
effects. However, this is dose dependent and CCK and amylin, e.g., at least acutely 
reduce eating in the absence of such effects. Whether the same is true of other gut-brain 
axis hormones such as GLP-1, its analogues, or PYY3-36 is less clear.  Although they 
potently reduce food intake, this effect is often accompanied by presumably 
gastrointestinal side effects leading to conditioned taste aversions in animals or nausea in 
humans.   
 
9.5.2.3 Route of administration. A disadvantage of brain-gut axis signals is that the 
peptide or peptidergic agonists or antagonists cannot be administered orally. This, of 
course, would not apply to non-peptide analogs.  Furthermore, the increasing recognition 
of the medical severity of obesity together with the advantages of gut-brain peptide 
therapies may soon be felt to justify injections as a route of administration. 
 
9.5.3 Relative strengths of  animal and human studies 
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This chapter  reviewed the control of eating in animals by gut-brain axis signals, 
focussing especially on hormonal gut-brain signals.  One may reasonably ask if animal 
research has particular strenghts in this area.  We believe that it does. 
 
As is the case with all other areas of behavioral neuroscience, one can perform many 
types of experiments in animals that cannot be done in humans. This includes long-term 
control of behavioral and physiological functions, for example, adaptation to particular 
diets, that help isolate phenomena of interest. Similarly, one can perform injurious or 
potentially injurious procedures in animals, including, for example, surgical, 
pharmacological and genetic lesions and, to name an example germane to behavioral 
endocrinology, cannulations of vasculature and endocrine organs, etc. These procedures 
permit less well controlled physiological studies in humans to be carefully validated in 
animals. As well, they permit extension and reduction of behavioral data to physiological 
and neurophysiological functions. 
 
This pertains particularly to gastrointestinal controls of eating. Gut-brain axis signals, and 
especially  hormonal signals, are easily accessible to experimental investigation 
in  both  animals and humans. This  permits the use of essentially identical experimental 
designs,  so that studies performed in animals can be done in parallel in humans. This 
allows  degree of direct validation of animal results  in human  subjects that is rarely 
possible in physiological research. Excellent examples of this can be found in the study 
of the satiating effects of CCK and other gut peptides (e.g., studies on synergistic actions 
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between preloads and CCK in rats, monkeys and humans; intestinal satiation with 
intraduodenal infusions of fat combined with CCK antagonism in rats and humans). 
 
Finally, it is important to note that in both animals and humans,  one can  study not 
only  pharmacological hormone action but also  normal endogenous hormone release 
simply by taking a blood sample. Thus, if one can sample a hormone between its site of 
release and the relevant receptors, then the ability to monitor and manipulate 
physiological signalling is limited only by the temporal resolution of infusions and 
measures. Nonetheless, this is not a trivial issue, as many hormones related to eating are 
released into the hepatic portal vein, which is less accessible than the systemic 
circulation, and, moreover, most have pulsatile patterns of release. Pulsatile release, of 
course, is a general phenomenon in endocrinology and not limited to gut-brain signals. 
Nevertheless, even considering these complications, the accessibility of hormonal 
signaling molecules remains incomparably greater than that of central neural signals.  We 
have detailed information as to the relevant prandial patterns of release of several 
endocrine controls of eating; with few exceptions (e.g., recent reports of dopamine 
release in the nucleus accumbens measured during sucrose or fat meals.83,84), almost no 
comparable information is available for any brain neurotransmitter. 
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Table 1. Gut peptides potentially involved in the physiological control of eating. 
----------------------------------------------------------------------------------------------------------- 
Peptide   Site(s) of production Site(s) of critical receptors  Reference 
----------------------------------------------------------------------------------------------------------- 
Amylin   Pancreatic B-cell  Area postrema (AP)  [8] 
 
Apolipoprotein A IV Villus epithelia  ?    [9] 
 
Bombesin-like peptides Stomach   Vagal and spinal visceral afferents [10] 
(GRP; neuromedin B) 
 
CCK   Proximal small intestine Vagal afferents in pyloric area; [6] 
      pyloric smooth muscle; liver 
 
Enterostatin  Exocrine pancreas ?    [11] 
 
Ghrelin   Stomach   Arcuate nucleus (Arc); AP; [12] 
      vagal afferents 
 
GLP-1   Ileum   Brainstem; hypothalamus  [13] 
 
Glucagon  Pancreatic A-cell  Liver    [14] 
 
Insulin   Pancreatic B-cell  Arc    [4] 
 
(gastric) Leptin  Stomach   Arc; vagal afferents; brainstem [4,15] 
 
PYY 3-36  Ileum   Hypothalamus   [16] 
----------------------------------------------------------------------------------------------------------- 
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Table 2.  Gut neural receptors potentially involved in the physiological control of eating 
--------------------------------------------------------------------------------------------------------- 
 Receptor site and characteristics  Reference 
--------------------------------------------------------------------------------------------------------- 
 Gastric mechanoreceptors   [17] 
 Hepatic chemoreceptors*   [18,19] 
 Hepatic thermoreceptors   [20] 
 Intestinal chemoreceptors*   [21,22] 
 Intestinal mechanoreceptors   [21] 
 Intestinal osmoreceptors   [7] 
----------------------------------------------------------------------------------------------------------- 
 *Note:  Here, chemoreceptors are broadly defined to include specific nutrients (e.g., 
glucose) or their digestive and metabolic products or consequences (e.g., lactate, changes 
in hepatocyte membrane potential, or changes in pH).   
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Table 3. Criteria for the physiological action of hormonal controls of eating5 
----------------------------------------------------------------------------------------------------------- 
(1) Secretion   Eating changes the secretion of the hormone. 
(2) Receptor   Receptors are present at the primary site of action. 
(3) Physiological dose The eating effect is reproduced by mimicking the secretion  
    pattern of the endogenous hormone by administration of the 
    hormone. This may perhaps only occur in synergy with  
    other endogenous stimuli. 
(4) Removal, replacement Removal of the hormone or the critical receptors prevents  
    the eating effect. Appropriate hormone replacement or  
    receptor rescue reproduces the effect. 
(5) Antagonism  The eating effect of the endogenous hormone is prevented  
    by selectively antagonizing the hormone signaling.  
    Selective antagonisms also prevents the eating effect of  
    physiological doses of the exogenous hormone. 
----------------------------------------------------------------------------------------------------------- 
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Table 4.  Functional interactions between CCK and other peripheral signals controlling 
eating. 
----------------------------------------------------------------------------------------------------------- 
 Signal    Nature of Interaction  Reference 
----------------------------------------------------------------------------------------------------------- 
 Amylin   Synergy   [8,80] 
 
 Estradiol   Synergy    [37] 
 
 Gastric load   Synergy   [6] 
 
 GLP-1    None    [13,81] 
 
 Pancreatic Glucagon  Antagonism   [82] 
 
 (central) Insulin  Synergy   [4] 
 
 Leptin    Synergy   [4] 
----------------------------------------------------------------------------------------------------------- 
Here, synergy is defined as a further decrease in eating when CCK and the other 
signal are applied simultaneously in comparison CCK alone. Antagonism is a smaller 
decrease in eating when CCK and the other signal are applied simultaneously. 
 
